KRAS and Obesity: In this regard, obesity and inflammation are considered among the most predominant clinical risk factors and are likely to synergize with mutant KRAS to drive pancreatic tumorigenesis leading to invasive PDAC, in which oncogenic KRAS is known to be hyperactivated (Figure 1C).